Derrick Gingery
Senior Writer
An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions
What's in – and what fell out of – the massive US stimulus package.
US FDA Would Get Funding Boost Under House Coronavirus Stimulus Bill
Agency appears to have a fair bit of flexibility in how to spend the additional $80m slated for coronavirus activities.
More FDA Funding In House Coronavirus Stimulus Bill, But No OTC Purchases With Pre-tax Savings
An additional $160m is allocated to FDA in House coronavirus-related stimulus bill aimed at fighting the pandemic and helping the wobbling economy. It would not, as a similar Senate bill proposes, once again allow using pre-tax savings accounts to buy OTC drugs.
As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?
Productivity may suffer under coronavirus-mandated telework despite workforce diligence, experts say.
As Chloroquine Demand Surges, Bayer Looks To Emergency Use Authorization To Enter US Market
Unlike diagnostics, EUAs for drugs are rare and the fact that there already are FDA-approved competitors for Bayer’s chloroquine phosphate product may make the decision more complicated.